司美格鲁肽对有症状外周动脉疾病合并2型糖尿病患者步行能力的影响(STRIDE):一项3b期双盲随机安慰剂对照试验
STRIDE为3b期双盲随机安慰剂对照试验,在20个国家112个中心纳入792例有症状外周动脉疾病合并2型糖尿病患者,随机接受司美格鲁肽1.0 mg每周一次或安慰剂治疗52周。主要终点第52周恒载平板最大步行距离较基线比值,司美格鲁肽组显著高于安慰剂组(估计治疗比值1.13,95%CI 1.06-1.21,p=0.0004)。
要点
- 司美格鲁肽1.0 mg每周一次治疗52周,显著提高最大步行距离较基线比值。
- 司美格鲁肽组与安慰剂组严重不良事件中可能或很可能与治疗相关者分别为5例(1%)和6例(2%)。
- 作者指出未来需进一步阐明获益机制,并评估无2型糖尿病的外周动脉疾病患者中的疗效与安全性。
核心结论
- 司美格鲁肽增加了有症状外周动脉疾病合并2型糖尿病患者的步行距离。
- 研究意义包括未来需进一步阐明获益机制,并评估无2型糖尿病的外周动脉疾病患者的疗效与安全性。
研究设计与样本
- STRIDE为双盲、随机、安慰剂对照试验,在北美、亚洲和欧洲20个国家的112个门诊临床试验中心进行。
- 纳入18岁及以上、2型糖尿病合并外周动脉疾病伴间歇性跛行(Fontaine IIa期,可行走>200 m)且踝臂指数≤0.90或趾臂指数≤0.70的患者。
- 采用交互式网络应答系统按1:1随机分配接受皮下司美格鲁肽1.0 mg每周一次或安慰剂治疗52周。
- 主要终点为全分析集中第52周恒载平板测得的最大步行距离较基线比值;安全性在安全性分析集中评估。
- 2020年10月1日至2024年7月12日筛查1363例,随机分配792例至司美格鲁肽组(n=396)或安慰剂组(n=396)。
主要发现
- 195例(25%)参与者为女性,597例(75%)为男性;中位年龄68.0岁(IQR 61.0-73.0)。
- 第52周最大步行距离较基线估计中位比值司美格鲁肽组为1.21(IQR 0.95-1.55),安慰剂组为1.08(IQR 0.86-1.36)。
- 估计治疗比值为1.13(95%CI 1.06-1.21),p=0.0004,司美格鲁肽组显著大于安慰剂组。
- 司美格鲁肽组5例(1%)参与者发生6起可能或很可能与治疗相关的严重不良事件,安慰剂组6例(2%)参与者发生9起。
- 最常见的可能或很可能与治疗相关的严重不良事件为严重胃肠道事件,司美格鲁肽组2例(1%)报告2起,安慰剂组3例(1%)报告5起;无治疗相关死亡。
局限性
- 作者指出未来需进一步阐明获益机制,并评估无2型糖尿病的外周动脉疾病患者的疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peripheral artery disease is a highly morbid type of atherosclerotic vascular disease involving the legs and is estimated to affect over 230 million individuals globally. Few therapies improve functional capacity and health-related quality of life in people with lower limb peripheral artery disease. We aimed to evaluate whether semaglutide improves function as measured by walking ability as well as symptoms, quality of life, and outcomes in people with peripheral artery disease and type 2 diabetes. METHODS: STRIDE was a double-blind, randomised, placebo-controlled trial done at 112 outpatient clinical trial sites in 20 countries in North America, Asia, and Europe. Participants were aged 18 years and older, with type 2 diabetes and peripheral artery disease with intermittent claudication (Fontaine stage IIa, able to walk >200 m) and an ankle-brachial index of less than or equal to 0·90 or toe-brachial index of less than or equal to 0·70. Participants were randomly assigned (1:1) using an interactive web response system to receive subcutaneous semaglutide 1·0 mg once per week for 52 weeks or placebo. The primary endpoint was the ratio to baseline of the maximum walking distance at week 52 measured on a constant load treadmill in the full analysis set. Safety was evaluated in the safety analysis set. This trial is registered with ClinicalTrials.gov, NCT04560998 and is now completed. FINDINGS: From Oct 1, 2020, to July 12, 2024, 1363 patients were screened for eligibility, of whom 792 were randomly assigned to semaglutide (n=396) or placebo (n=396). 195 (25%) participants were female and 597 (75%) were male. Median age was 68·0 years (IQR 61·0-73·0). The estimated median ratio to baseline in maximum walking distance at week 52 was significantly greater in the semaglutide group than the placebo group (1·21 [IQR 0·95-1·55] vs 1·08 [0·86-1·36]; estimated treatment ratio 1·13 [95% CI 1·06-1·21]; p=0·0004). Six serious adverse events in five (1%) participants in the semaglutide group and nine serious adverse events in six (2%) participants in the placebo group were possibly or probably treatment related, with the most frequent being serious gastrointestinal events (two events reports by two [1%] in the semaglutide group and five events reported by three [1%] in the placebo group). There were no treatment-related deaths. INTERPRETATION: Semaglutide increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes. Research implications include the need for future studies to further elucidate mechanisms of benefit and to assess the efficacy and safety in patients with peripheral artery disease who do not have type 2 diabetes. FUNDING: Novo Nordisk.
引用
- Bonaca MP, Catarig AM, Houlind K, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025. PMID: 40169145. doi:10.1016/S0140-6736(25)00509-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。